{"id":52628,"date":"2023-01-06T14:02:29","date_gmt":"2023-01-06T13:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/"},"modified":"2023-01-06T14:02:29","modified_gmt":"2023-01-06T13:02:29","slug":"synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/","title":{"rendered":"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics"},"content":{"rendered":"
\n

\nFunds to support continued clinical development of selective IL-2 partial agonist, STK-012, and orthogonal IL-2 + CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, as well as advancement of preclinical pipeline<\/i>\n<\/p>\n

\nCompany to present at 41st<\/sup> Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT on January 10, 2023<\/i>\n<\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE)–#Synthekine<\/a>—Synthekine Inc.<\/a>, an engineered cytokine therapeutics company, today announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors. Debanjan Ray, Synthekine\u2019s chief executive officer, will present a corporate overview at the 41st<\/sup> Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT on Tuesday, January 10.\n<\/p>\n

<\/a><\/p>\n

\n\u201cSynthekine has made significant progress since our founding in 2019. We have advanced our alpha\/beta-biased IL-2 partial agonist, STK-012, into the clinic, developed a novel cytokine approach to empower CAR-Ts and other adoptive cell therapies, matured our three distinct cytokine engineering platforms, and secured our first pharmaceutical partnership through a deal with Merck,\u201d said Ray. \u201cWe are thankful for the support from these elite healthcare investors, which enables us to pursue our bold vision of advancing novel cytokine science to benefit patients with debilitating cancers and inflammatory diseases.\u201d\n<\/p>\n

\nProceeds of the financing will be used to advance Synthekine\u2019s differentiated therapeutic pipeline, led by its alpha\/beta-biased IL-2 partial agonist, STK-012, which is currently<\/a> in a Phase 1 clinical trial. In addition, it will support upcoming clinical studies of its orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001<\/a>, which the company anticipates to begin early this year.\n<\/p>\n

\nFunds will also be used to progress the company\u2019s IL-12 partial agonist program, which is currently in IND-enabling studies. IL-12 is a potent cytokine with potential for the treatment of cancer, but administration of unmodified forms of the cytokine have been limited by a narrow therapeutic window, including life-threatening toxicities in patients. Preclinical data for Synthekine\u2019s IL-12 partial agonist program demonstrates potent anti-tumor efficacy in mouse models while avoiding induction of systemic toxicity. In addition, funds will also be used to advance toward clinical investigation its orthogonal IL-2 system with a GPC3 CAR-T therapy. Preclinical data for this program, the company\u2019s first cell therapy program for solid tumors, were presented at AACR 2022<\/a>.\n<\/p>\n

\nAbout Synthekine<\/b>\n<\/p>\n

\nSynthekine is harnessing the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatment paradigm of cancer and inflammatory disease. Using insights on cytokine structure and function, the company engineers therapeutics designed to unlock the full efficacy potential of cytokines while avoiding their associated toxicities. Synthekine is applying principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms to create a broad and deep pipeline of product candidates. These novel immunotherapies include modified cytokines, cytokine-enhanced cell therapies and surrogate cytokine agonists. For more information, visit www.synthekine.com<\/a>, and follow us on Twitter @synthekine<\/a> and LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nWill Zasadny
\n
Evoke Canale
\n
619-961-8848
\n
will.zasadny@evokegroup.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Funds to support continued clinical development of selective IL-2 partial agonist, STK-012, and orthogonal IL-2 + CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, as well as advancement of preclinical pipeline Company to present at 41st Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT on January 10, 2023 MENLO PARK, Calif.–(BUSINESS WIRE)–#Synthekine—Synthekine Inc., an engineered … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52628","6":"format-standard","7":"category-industry"},"yoast_head":"\nSynthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Funds to support continued clinical development of selective IL-2 partial agonist, STK-012, and orthogonal IL-2 + CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, as well as advancement of preclinical pipeline Company to present at 41st Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT on January 10, 2023 MENLO PARK, Calif.–(BUSINESS WIRE)–#Synthekine—Synthekine Inc., an engineered ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-06T13:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230106005065\/en\/1678826\/21\/SynthekineLogo-update.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics\",\"datePublished\":\"2023-01-06T13:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/\"},\"wordCount\":500,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005065\\\/en\\\/1678826\\\/21\\\/SynthekineLogo-update.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/\",\"name\":\"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005065\\\/en\\\/1678826\\\/21\\\/SynthekineLogo-update.jpg\",\"datePublished\":\"2023-01-06T13:02:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005065\\\/en\\\/1678826\\\/21\\\/SynthekineLogo-update.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230106005065\\\/en\\\/1678826\\\/21\\\/SynthekineLogo-update.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics - Pharma Trend","og_description":"Funds to support continued clinical development of selective IL-2 partial agonist, STK-012, and orthogonal IL-2 + CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, as well as advancement of preclinical pipeline Company to present at 41st Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT on January 10, 2023 MENLO PARK, Calif.–(BUSINESS WIRE)–#Synthekine—Synthekine Inc., an engineered ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-06T13:02:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230106005065\/en\/1678826\/21\/SynthekineLogo-update.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics","datePublished":"2023-01-06T13:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/"},"wordCount":500,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005065\/en\/1678826\/21\/SynthekineLogo-update.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/","url":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/","name":"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230106005065\/en\/1678826\/21\/SynthekineLogo-update.jpg","datePublished":"2023-01-06T13:02:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230106005065\/en\/1678826\/21\/SynthekineLogo-update.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230106005065\/en\/1678826\/21\/SynthekineLogo-update.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/synthekine-secures-100-million-series-c-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52628"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52628\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}